<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02930889</url>
  </required_header>
  <id_info>
    <org_study_id>G16004/A002</org_study_id>
    <nct_id>NCT02930889</nct_id>
  </id_info>
  <brief_title>Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)</brief_title>
  <official_title>Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a investigator-initiated evaluation of the safety and efficacy of treating benign
      prostatic hyperplasia (BPH) by prostatic artery embolization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a investigator-initiated evaluation of the safety and efficacy of treating benign
      prostatic hyperplasia (BPH) by prostatic artery embolization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>3 Months</time_frame>
    <description>All adverse events will be collected and reviewed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>International prostate symptom score</measure>
    <time_frame>3 months</time_frame>
    <description>Subject will complete a questionnaire regarding symptoms Scale of 1-5 regarding symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>3 months</time_frame>
    <description>Quality of Life questionnaire will be administered at 3 month visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post void Residual</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Urinary Flow Rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen</measure>
    <time_frame>3 months</time_frame>
    <description>he post-void residual (PVR) urine test measures the amount of urine left in the bladder after urination.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Prostate Artery Embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prostate Artery Embolization</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prostate Artery Embolization</intervention_name>
    <description>Prostate Artery Embolization</description>
    <arm_group_label>Prostate Artery Embolization</arm_group_label>
    <other_name>PAE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria:

          -  Male, 45 years or older

          -  Diagnosis of Lower Urinary Tract Symptoms from Benign Prostatic Hyperplasia refractory
             to medical therapy for at least 6 months.

          -  IPSS score at initial evaluation should be greater than 12, and uroflowmetry (Qmax) of
             &lt;15mL/s (milliliters per second).

          -  All prostate volumes will be &gt; 40gm

          -  PSA which meets one of the following criteria:Baseline PSA ≤ 2.5ng/mL, Baseline PSA &gt;
             2.5 ng/mL and ≤ 10 ng/mL AND free PSA ≥ 25% of total PSA (no biopsy required);Baseline
             PSA &gt; 2.5 ng/mL and ≤ 10 ng/mL AND free PSA &lt; 25% of total PSA AND negative prostate
             biopsy result (minimum of 12 core biopsy) within 12 months;Baseline PSA &gt;10 ng/mL AND
             negative prostate biopsy result (minimum of 12 core biopsy) within 12 months;Negative
             prostate biopsy (minimum 12 cores within 12 months) if abnormal digital rectal
             examination.

        Exclusion Criteria:

          -  Patients with active urinary tract infections or recurrent urinary tract infections (&gt;
             2/year), prostatitis, or interstitial cystitis.

          -  Cases of biopsy proven prostate, bladder, or urethral cancer.

          -  Patients on long-term narcotic analgesia, androgen therapy, or GNRH
             (gonadotropin-releasing hormone) analogue therapy who are unwilling to stop therapy
             for 2 months prior to the study.

          -  Use of anithistamines, anti-convulsants, and antispasmodics within one week of
             treatment unless they have been treated with the same drug (at the same dosage) for at
             least 6 months and has an associated stable voiding pattern.

          -  Patients who are classified as New York Heart Association Class III (Moderate), or
             higher, have cardiac arrhythmias, have uncontrolled diabetes, or are known to be
             immunosuppressed.

          -  Hypersensitivity reactions to contrast material not manageable with prophylaxis.

          -  Patients with glomerular filtration rates less than 40 who are not already on dialysis

          -  Prostate volume &lt;40 mL

          -  Patients with bilateral internal iliac arterial occlusion

          -  Patients with causes of bladder obstruction not due to BPH (eg urethral stricture,
             bladder neck contraction, etc)

          -  Patients with neurogenic or bladder atonia

          -  Prior prostatectomy

          -  Cystolithiasis within the last 3 months

          -  Patients interested in future fertility

          -  Patients with a life expectancy less than 1 year

          -  Patients where embolization is not possible distal to collateral vessels feeding
             non-prostatic tissue

          -  Patients with major neurologic illnesses which could have symptoms that may be similar
             to or confused for BPH (eg Parkinson's disease, multiple sclerosis, Shy-Drager
             syndrome, spinal cord injury, etc.).

          -  Patients with urethral stents

          -  Patients who have undergone prior rectal surgery other than hemorrhoidectomy or pelvic
             irradiation.

          -  Patients who have started or changed their dosage of alpha blockers or 5-alpha
             reductase inhibitors in the month prior to PAE
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jafar Golzarian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shamar J Young, MD</last_name>
    <phone>612-626-5388</phone>
    <email>youn1862@umn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jafar Golzarian, MD</last_name>
    <phone>612-626-5388</phone>
    <email>jafar@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shamar J Young, MD</last_name>
      <phone>612-626-5388</phone>
      <email>youn1862@umn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jafar Golzarian, MD</last_name>
      <phone>612-626-5388</phone>
      <email>jafar@umn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jafar Golzarian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shamar Young, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2016</study_first_submitted>
  <study_first_submitted_qc>October 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2016</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Therapeutic Embolization</keyword>
  <keyword>Prostatic Artery Embolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

